About Latona Life Sciences

Latona Life Sciences, Inc. is a privately-held specialty pharmaceutical company dedicated to the development and commercialization of pharmaceuticals in key therapeutic orphan drug markets.

The company has acquired the rights to the first oral human immunoglobulin, Oralgam™. This product shows potential to serve the Juvenile Idiopathic Arthritis market as well as other immune-mediated diseases.

Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Current estimates of incidence of JIA in the U.S. range from approximately 10 – 100/100,000 children, resulting in current estimates of approximately 100,000 patients under the age of 18.

Immune-Mediated Diseases

The fundamental concept is that immune-mediated disease results from a selective deficiency in the mucosal immune system of a susceptible individual. The disease process is initiated in the intestinal tract, although the effects of the disease process manifest themselves in tissues and organs far from the intestinal tract. The disease process can be reversed by interfering with this critical step in the expression of immune-mediated disease.

Therapeutic Areas

Latona Life Sciences, Inc. is focused on developing orphan drugs for immune-mediated diseases. Oralgam™ has been granted Orphan Drug Status by the FDA for Juvenile Idiopathic Arthritis (JIA), Dermatomyositis, and autistic enterocolitis.

Investing in Latona Life Sciences, Inc.

Latona is a privately-held specialty company dedicated to the development and commercialization of pharmaceuticals in key therapeutic orphan drug markets.